Morphic only had eyes for Eli Lilly. While some takeover tales have casts of Shakespearean breadth, Lilly’s $3.2 billion Morphic buyout is a simpler story of two companies gradually closing the gap ...
WALTHAM, Mass.–(BUSINESS WIRE)–Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the closing of its ...
Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced Monday, a transaction that includes an experimental medication for inflammatory ...
Morphic Therapeutic has lost another Big Pharma partner. Eleven months after AbbVie walked away, Johnson & Johnson has delivered the killer blow to its own already-diminishing ties to the biotech. J&J ...
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ...
Morphic Ethical Equities Fund Ltd. ( ($AU:MEC) ) has issued an update. Morphic Ethical Equities Fund Limited has updated the market on its ongoing ...
Filed first IND of an oral integrin drug candidate, MORF-057, generated by Morphic’s MInT Platform and initiated first clinical study of MORF-057 in healthy volunteers in Phase 1 clinical trial of ...
First orally available integrin inhibitor from MInT Platform to enter the clinicMORF-057, inhibitor of α4β7 integrin, in development to treat inflammatory bowel diseasePhase 1 program to assess safety ...
A series of positive news is helping the biopharmaceutical company start the week on a strong note. Morphic Holding reported interim data from a phase 1 clinical trial for MORF-057, a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback